These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1627572)

  • 21. Comparison of the effects of Apo(a) kringle IV-10 and plasminogen kringles on the interactions of lipoprotein(a) with regulatory molecules.
    Xue S; Green MA; LoGrasso PV; Boettcher BR; Madison EL; Curtiss LK; Miles LA
    Thromb Haemost; 1999 Mar; 81(3):428-35. PubMed ID: 10102473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation.
    Feric NT; Boffa MB; Johnston SM; Koschinsky ML
    J Thromb Haemost; 2008 Dec; 6(12):2113-20. PubMed ID: 18983515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(a), fibrin binding, and plasminogen activation.
    Loscalzo J; Weinfeld M; Fless GM; Scanu AM
    Arteriosclerosis; 1990; 10(2):240-5. PubMed ID: 2138452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance.
    Hancock MA; Spencer CA; Koschinsky ML
    Biochemistry; 2004 Sep; 43(38):12237-48. PubMed ID: 15379562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100.
    Koschinsky ML; Côté GP; Gabel B; van der Hoek YY
    J Biol Chem; 1993 Sep; 268(26):19819-25. PubMed ID: 8366120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells.
    Koschinsky ML; Tomlinson JE; Zioncheck TF; Schwartz K; Eaton DL; Lawn RM
    Biochemistry; 1991 May; 30(20):5044-51. PubMed ID: 2036372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lysine-binding heterogeneity of Lp(a): consequences for fibrin binding and inhibition of plasminogen activation.
    Bas Leerink C; Duif PF; Gimpel JA; Kortlandt W; Bouma BN; van Rijn HJ
    Thromb Haemost; 1992 Aug; 68(2):185-8. PubMed ID: 1412165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hedgehog lipoprotein(a) is a modulator of activation of plasminogen at the fibrin surface. An in vitro study.
    Rouy D; Laplaud PM; Saboureau M; Anglés-Cano E
    Arterioscler Thromb; 1992 Feb; 12(2):146-54. PubMed ID: 1531929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
    de Vries C; Veerman H; Koornneef E; Pannekoek H
    J Biol Chem; 1990 Aug; 265(23):13547-52. PubMed ID: 2143185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of sequences in apolipoprotein(a) that maintain its closed conformation: a novel role for apo(a) isoform size in determining the efficiency of covalent Lp(a) formation.
    Becker L; Cook PM; Koschinsky ML
    Biochemistry; 2004 Aug; 43(31):9978-88. PubMed ID: 15287725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping of a minimal apolipoprotein(a) interaction motif conserved in fibrin(ogen) beta - and gamma -chains.
    Klose R; Fresser F; Kochl S; Parson W; Kapetanopoulos A; Fruchart-Najib J; Baier G; Utermann G
    J Biol Chem; 2000 Dec; 275(49):38206-12. PubMed ID: 10980194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells.
    Romagnuolo R; DeMarco K; Scipione CA; Boffa MB; Koschinsky ML
    Thromb Res; 2018 Sep; 169():1-7. PubMed ID: 29990619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural domains of apolipoprotein(a) and its interaction with apolipoprotein B-100 in the lipoprotein(a) particle.
    Huby T; Doucet C; Dieplinger H; Chapman J; Thillet J
    Biochemistry; 1994 Mar; 33(11):3335-41. PubMed ID: 8136370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin.
    Bok RA; Mangel WF
    Biochemistry; 1985 Jun; 24(13):3279-86. PubMed ID: 3161540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu.
    Rouy D; Grailhe P; Nigon F; Chapman J; Anglés-Cano E
    Arterioscler Thromb; 1991; 11(3):629-38. PubMed ID: 1827591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apolipoprotein(a): structure-function relationship at the lysine-binding site and plasminogen activator cleavage site.
    Anglés-Cano E; Rojas G
    Biol Chem; 2002 Jan; 383(1):93-9. PubMed ID: 11928826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidation of apolipoprotein(a) inhibits kringle-associated lysine binding: the loss of intrinsic protein fluorescence suggests a role for tryptophan residues in the lysine binding site.
    Hermann A; Laws WR; Harpel PC
    Protein Sci; 1997 Nov; 6(11):2324-35. PubMed ID: 9385634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophils stimulated by apolipoprotein(a) generate fragments that are stronger inhibitors of plasmin formation than apo(a).
    Lamanuzzi LB; Mtairag el M; Pepe G; Anglés-Cano E
    Thromb Haemost; 2004 Nov; 92(5):1066-75. PubMed ID: 15543335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual effect of apolipoprotein(a) on plasmin(ogen)-induced apoptosis through modulation of cell detachment of adherent cells.
    Ho-Tin-Noé B; Meilhac O; Rossignol P; Lijnen HR; Anglés-Cano E
    Thromb Haemost; 2006 Jan; 95(1):142-50. PubMed ID: 16543973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation.
    Sangrar W; Bajzar L; Nesheim ME; Koschinsky ML
    Biochemistry; 1995 Apr; 34(15):5151-7. PubMed ID: 7711034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.